Fluorescence endoscopy of cathepsin activity discriminates dysplasia from colitis

Inflammatory Bowel Diseases

Volumn 19, Issue 7, 2013, Pages 1339-1345

  Gounaris, Elias ^a   Martin, John ^a   Ishihara, Yasushige ^b   Khan, Mohammad Wasim ^a   Lee, Goo ^a   Sinh, Preetika ^a   Chen, Eric Zongming ^a   Angarone, Michael ^a   Weissleder, Ralph ^c   Khazaie, Khasharyasha ^a   Barrett, Terrence A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Research and Development Division   (Japan)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cathepsin activity; Colitis; Dysplasia; Fluorescence endoscopy; Macrophages

Indexed keywords

CATHEPSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; COLITIS; COLON ADENOCARCINOMA; COLONOSCOPY; CONTROLLED STUDY; FLUORESCENCE IMAGING; GASTROINTESTINAL DYSPLASIA; HUMAN; HUMAN TISSUE; INFRARED RADIATION; MACROPHAGE; MOLECULAR PROBE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; SUPPRESSOR CELL;

ADENOCARCINOMA; ANIMALS; CATHEPSINS; CELLS, CULTURED; COLITIS; COLON; ENDOSCOPY; FLUORESCENCE; HUMANS; INTERLEUKIN-10; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID CELLS; PRECANCEROUS CONDITIONS; SIGNAL-TO-NOISE RATIO;

EID: 84879081854     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e318281f3f8     Document Type: Review

References (22)

1. Rutter MD, Saunders BP, Schofield G, et al. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut. 2004;53:256-260.
2. Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004;53:1813-1816.
3. Marion JF, Waye JD, Present DH, et al. Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol. 2008;103:2342-2349.
4. Ullman TA. Inflammatory bowel disease-associated cancers: does gender change incidence? Gastroenterology. 2010;138:1658-1660.
5. Mason SD, Joyce JA. Proteolytic networks in cancer. Trends Cell Biol. 2011;21:228-237.
6. Connell WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology. 1994;107:934-944.
7. Farraye FA, Odze RD, Eaden J, et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:746-774, 774.e1-e4; quiz e12-e3.
8. Jess T, Loftus EV, Velayos FS, et al. Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis. 2006;12:669-676.
9. Awais D, Siegel CA, Higgins P D R. Modelling dysplasia detection in ulcerative colitis: clinical implications of surveillance intensity. Gut. 2009;58:1498-1503.
10. Choi PM, Nugent FW, Schoetz DJ, et al. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology. 1993;105:418-424.
11. Kiesslich R, Goetz M, Lammersdorf K, et al. Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology. 2007;132:874-882.
12. Rutter MD, Saunders BP, Wilkinson KH, et al. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc. 2004;60:334-339.
13. Rutter MD. Surveillance programmes for neoplasia in colitis. J Gastroenterol. 2011;46(Suppl 1):1-5.
14. Ullman T, Lazarev M. Scope early and often in ulcerative colitis and Crohn's colitis? Gastroenterology. 2009;136:718-719; discussion 719-720.
15. Weissleder R, Tung CH, Mahmood U, et al. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol. 1999;17:375-378.
16. Cattaruzza F, Lyo V, Jones E, et al. Cathepsin S is activated during colitis and causes visceral hyperalgesia by a PAR2-dependent mechanism in mice. Gastroenterology. 2011;141:1864-1874.e1-e3.
17. Gounaris E, Tung CH, Restaino C, et al. Live imaging of cysteine-cathepsin activity reveals dynamics of focal inflammation, angiogenesis, and polyp growth. PLoS ONE. 2008;3:e2916.
18. Gocheva V, Wang H-W, Gadea BB, et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev. 2010;24:241-255.
19. De Nardo DG, Johansson M, Coussens LM. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev. 2008;27:11-18.
20. Youn J-I, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol. 2010;40:2969-2975.
21. Brown JB, Lee G, Managlia E, et al. Mesalamine inhibits epithelial betacatenin activation in chronic ulcerative colitis. Gastroenterology. 2010;138:595-605, 605.e1-e3.
22. Truelove SC, Richards WC. Biopsy studies in ulcerative colitis. Br Med J. 1956;1:1315-1318.